Avalere
GLP-1 Market Analysis Includes Managed Medicaid Claims Data on Utilization Patterns
Avalere analyzed pharmacy claims across payer types including Managed Medicaid to assess on-label and off-label use of GLP-1 and GIP/GLP-1 receptor agonists for diabetes and weight management. The piece examines product differentiation strategies for manufacturers and notes that USP Drug Classification limitations affect coverage decisions in non-Part D plans. While focused primarily on manufacturer strategy and market dynamics, the analysis incorporates Medicaid managed care data and touches on formulary implications relevant to MCO pharmacy benefit management.
This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.